Who
Pierre Sargis Sayad
Chief Medical Officer
Company insider
Files Form 4 as: Chief Medical Officer, Fennec Pharmaceuticals.
In numbers
- Trades disclosed
- 24
- Buys
- 0
- Sells
- 1
- Bought
- $0
- Sold
- $292K
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 13 Nov 2024
- Last trade
- 12 Oct 2026
- Last filed
- 13 Oct 2026
Companies traded
Activity over time
1 Aug – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 12 Oct 2026filed 13 Oct 2026 | FENC Fennec PharmaceuticalsBiotechnology | SEC FORM 4 Code A | $21K3,846 at $5.53 | filing |
| 30 Sep 2026filed 1 Oct 2026 | FENC Fennec PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —168 at $0.00 | filing |
| 31 Aug 2026filed 31 Aug 2026 | FENC Fennec PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —168 at $0.00 | filing |
| 31 Aug 2026filed 31 Aug 2026 | FENC Fennec PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $146K12,000 at $12.18 | filing |
| 31 Aug 2026filed 31 Aug 2026 | FENC Fennec PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —168 at $0.00 | filing |
| 31 Aug 2026filed 31 Aug 2026 | FENC Fennec PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $146K12,000 at $12.18 | filing |
| 31 Jul 2026filed 3 Aug 2026 | FENC Fennec PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —168 at $0.00 | filing |
| 31 Jul 2026filed 3 Aug 2026 | FENC Fennec PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —168 at $0.00 | filing |
| 30 Jun 2026filed 1 Jul 2026 | FENC Fennec PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —168 at $0.00 | filing |
| 30 Jun 2026filed 1 Jul 2026 | FENC Fennec PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —168 at $0.00 | filing |
| 31 May 2026filed 1 Jun 2026 | FENC Fennec PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —168 at $0.00 | filing |
| 31 May 2026filed 1 Jun 2026 | FENC Fennec PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —168 at $0.00 | filing |
| 30 Apr 2026filed 1 May 2026 | FENC Fennec PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —168 at $0.00 | filing |
| 30 Apr 2026filed 1 May 2026 | FENC Fennec PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —168 at $0.00 | filing |
| 31 Mar 2026filed 2 Apr 2026 | FENC Fennec PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —18,456 at $0.00 | filing |
| 31 Mar 2026filed 2 Apr 2026 | FENC Fennec PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —171 at $0.00 | filing |
| 31 Mar 2026filed 2 Apr 2026 | FENC Fennec Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | $692K120,000 at $5.77 | filing |
| 31 Mar 2026filed 2 Apr 2026 | FENC Fennec Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | $692K120,000 at $5.77 | filing |
| 31 Mar 2026filed 2 Apr 2026 | FENC Fennec PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —18,456 at $0.00 | filing |
| 31 Mar 2026filed 2 Apr 2026 | FENC Fennec PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —171 at $0.00 | filing |
News
Head-To-Head Review: Adherex Technologies (NASDAQ:FENC) versus Jaguar Animal Health (NASDAQ:JAGX)FENC · dailypolitical.com · 22 Oct 2026
0 headlines in the last 90 days name Pierre Sargis Sayad; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.